Asian press release distribution - ACN Newswire

|

|

|

|

Press Releases for Friday, February 10, 2023

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases 21:06 HKT/SGT

亿胜生物宣布贝伐珠单抗眼科适应症国际多中心III期临床研究完成美国首例患者给药 20:39 HKT/SGT

億勝生物宣佈貝伐珠單抗眼科適應症國際多中心III期臨床研究完成美國首例患者給藥 20:38 HKT/SGT

XOX Strengthens Presence in Local Football Scene with KLCFC Partnership 19:00 HKT/SGT

Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific 19:00 HKT/SGT

Bintai Kinden Wins RM14.2 Million Project from TNB 18:00 HKT/SGT

百果园年货节成绩亮眼：全渠道终端零售额超13亿元，三四线市场消费升级明显 17:07 HKT/SGT

百果園年貨節成績亮眼：全渠道終端零售額超13億元，三四線市場消費升級明顯 17:06 HKT/SGT

Infocus International Brings Back Renewable Energy Project Finance & Financial Modelling Masterclass 16:07 HKT/SGT

ソニーグループ、急な暑さやほてりを個人に合わせた温度調節を通じてサポートするクラウドプラットフォームを活用したコネクテッドサービス「REON WIZ」提供開始 16:00 HKT/SGT

Honda、「Dio110」のカラーリング設定を変更するとともに、「Dio110・ベーシック」をタイプ追加し発売 14:00 HKT/SGT

マツダ、2023年3月期第3四半期決算を発表 14:00 HKT/SGT

Hong Kong's Middle East mission lays groundwork for new business opportunities 13:00 HKT/SGT

Former Singapore Parliamentarian's Swiss Digital Assets Company Receives Regulatory Approval 10:45 HKT/SGT

中部電力・デンソーなど、BEVを活用したエネルギーマネジメントシステムの試験導入開始 10:00 HKT/SGT

NECと筑波大学、顔映像から浮腫の度合いを推定する世界初の技術を開発 10:00 HKT/SGT

ACN Search:

Vice President Ma'ruf Amin waves to residents in the Malawei Fishing Village, Sorong Manoi District, Sorong City, West Papua, on 6 June 2024. The Indonesian government targeted building 350 houses for indigenous Papuan fishers in 2014, but only 40 houses have been completed due to technical constraints, including environmental impact assessments (AMDAL permits). The remaining houses will be completed in 2024/25. (ANTARA FOTO/Olha Mulalinda/Spt.)

Copyright © 2024 ACN Newswire - Asia Corporate News Network


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575